MOGAD

Early Escalation of Acute Treatment Reduces Relapse Risk in Pediatric MOG Antibody-Associated Disease

In pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), escalation of acute immunotherapy beyond steroids at first attack is linked to significantly fewer relapses within one year and mid-term follow-up, highli